Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2020 the compensation committee of the Company's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 51,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the "Inducement Plan"). The stock options were granted as an inducement material to the new employee's becoming an employee of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $5.45 per share, which is equal to the closing price of ImmunoGen's common stock on the Nasdaq Global Select Market on November 30, 2020. Each option will vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to such employee's continued employment with ImmunoGen on such vesting dates. Each option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now."

Learn more about who we are, what we do, and how we do it at www.immunogen.com.


These press releases may also interest you

at 21:52
In 2020, the global economy faced the impacts of the COVID-19 pandemic and the US-China trade war. While the economies around the world were critically affected, Taiwan was able to break through the predicament and make extraordinary performances in...

at 21:42
BioLineRx Ltd. , a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis...

at 20:55
Kiromic BioPharma, Inc. , an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and...

at 20:45
The virtual Explore Waterloo Region esports camps will provide top level instruction to campers between the ages of 12-19, designed to help them improve their gaming abilities, while also building important life skills that extend beyond the game....

at 20:27
Videotron Ltd. ("Videotron") today announced the pricing of its new issuance of C$650 million aggregate principal amount of 3.125% Senior Notes due 2031. The new senior notes will be sold at par, will carry a coupon of 3.125% and will mature on...

at 20:00
TZP Strategies Acquisition Corp. (the "Company"), a blank check company sponsored by TZP Group Holdings, L.P. ("TZP") and formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar...



News published on 1 december 2020 at 16:35 and distributed by: